Furthermore, immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway are authorized for treating several cancers, including classical Hodgkin lymphoma and head and neck squamous cell carcinoma [11]. This evidence concerns the gene CD274 and cancer.